Off-Label Use a More Attractive Tack?
Roche Won't Move Avastin To FDA in Ovarian Cancer
By Marie Powers
Tuesday, January 3, 2012
One week after the European Commission approved the use of Avastin (bevacizumab) in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer, findings from two Phase III studies published in the New England Journal of Medicine suggested the drug offered a modest but noticeable benefit over standard chemotherapy in terms of progression-free survival (PFS).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.